Vinge advises EQT Healthcare Growth, a new dedicated healthcare buy-out strategy introduced by EQT, in connection with its first investment – the acquisition of the biotech company, Mabtech, from IK Small Cap II Fund and several minority sellers.

EQT Healthcare Growth is a new buy-out strategy that builds on EQT’s 30-year healthcare track record, focused on scaling innovative, fast-growing healthcare companies to help deliver positive outcomes across the value chain. By helping companies build commercial muscle and expand their global reach, the strategy aims to enable the development of medical research, diagnostics, tools and treatments to deliver more efficient and accessible healthcare.

Mabtech is a category leading provider of tests and kits for studying immune responses predominantly in vaccine, infectious diseases, and oncology research. The company is based in Sweden and has over 900 customers in more than 60 countries. EQT Healthcare Growth will support Mabtech as it looks to expand its scale and reach.

The transaction is subject to customary conditions and approvals and is expected to close in Q1 2024.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson, Robin Sultani and Filip Magnusson (M&A), Stojan Arnerstål and Rebecka Målquist (IPR), Louise Brorsson Salomon, Helena Göransson, Kamyar Najmi and August Ahlin (Financing), Christoffer Nordin and Rebecka Danelius Gedin (Agreements and Permits), Mika Jordan and Elis Allmark (IT), Nicklas Thorgerzon and Lisa Hörnqvist (GDPR), Gulestan Ali (Employment), Kristoffer Larson (Real Estate), Mia Falk, Sam Fakhraie Ardekani and Maja Höglund (Compliance and Sanctions), Sebastian Örndahl, Daniel Wendelsson, Dagne Sabockis, Lovisa Lewin and Hilda Ivarson (Regulatory) and Gabriella Balbo (Transaction Support Coordinator).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025